Pubblicazioni scientifiche sui diagnostici non invasivi BioPredictive
Studi sottoposti a revisione paritaria che convalidano i diagnostici ematici BioPredictive per le malattie del fegato — dalle coorti di sviluppo pionieristiche alle meta-analisi a lungo termine.
89/434
Risultati per
“insulin”
-
Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
…and determinants of steatosis and insulin resistance (IR) in CHB and its…
-
The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.
### Unlabelled Introduction and aim. Given that early identification of non-alcoholic fatty…
-
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
…association of this parameter with insulin resistance (IR) and liver histology. ### Methods…
-
Glycogenic hepatopathy. Review
### Background Glycogenic hepatopathy (GH) is a disorder associated with uncontrolled diabetes mellitus…
-
Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.
### Unlabelled Physical activity (PA) is commonly recommended for nonalchoholic fatty liver disease…
-
Silymarin in non alcoholic fatty liver disease.
### Aim This study was undertaken to evaluate the hepatic effects of silybum…
-
Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.
…BMI), untreated sleep apnoea and insulin resistance, and, in addition, COPD Global…
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
…HD-UDCA also significantly improved markers of glycemic control and insulin resistance…
-
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.
…after adjustment for confounders, including insulin resistance. ### Conclusions A modest daily caffeine…
-
Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.
### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…
-
Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.
…Hyperlipidaemic patients have multiple risk factors of insulin resistance. It is impossible…
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…
-
Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.
…One child developed a deleterious metabolic phenotype with obesity and insulin resistance…
-
Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.
…triglyceride levels (P<.0001) and insulin resistance (P=.0004) as well as…
-
Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.
…39), homeostasis model assessment of insulin resistance (r=0.46), and MR…
-
Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.
### Background African Americans have lower reported likelihood of hepatitis C virus-related…
-
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication
### Background Liver biopsy is considered as the gold standard for assessing non…
-
[The prevalence of liver and gallbladder pathologies in overweight and obese patients].
…The occumrrence of insulin iresistance increased with BMI (p = 0.0001). Nonalcoholic…
-
Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.
Retrospective studies suggest that coffee consumption may exert beneficial effects in patients…
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…
-
PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.
…independent of visceral adiposity and insulin resistance. ### Objective In this study, we…
-
Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.
### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…
-
Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.
### Background Studies have demonstrated that both lower limb arterial calcification and metabolic…
-
Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.
### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease…
-
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication
### Background Liver biopsy is considered the gold standard for assessing histologic lesions…
-
Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.
### Background And Objective Obstructive sleep apnoea (OSA) could be an independent risk…
-
Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.
### Aim To compare noninvasive methods presently used for steatosis detection and quantification…
-
Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.
### Background Liver fibrosis in human immunodeficiency virus (HIV)-infected individuals is mostly…
-
Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.
### Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common…
-
Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.
Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review
-
Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
### Background HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver…
-
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.
### Aims To evaluate the application of the recently proposed recommendations by the…
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
-
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Review
The correct identification of patients at increased risk of non-alcoholic steatohepatitis…
-
Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.
The diagnostic utilities of ultrasonography (US), fatty liver index (FLI) and an…
-
Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.
### Introduction Long-term tenofovir disoproxil fumarate (TDF) use has been associated with…
-
Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.
The relationship between nonalcoholic fatty liver disease (NAFLD) and obstructive sleep apnea…
-
The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.
### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…
-
Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.
### Background Steatosis is common in patients with hepatitis C virus (HCV) infection…
-
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
Fibromax is a diagnostic tool composed of the combination of 4 non…
-
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.
### Background Studies have demonstrated that coronary artery calcification on one hand and…
-
Management of the patient with SVR. Review
In the current era of therapy with direct-acting antiviral (DAAs) drugs…
-
Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.
### Background No prospective diagnostic studies have directly compared widespread non-invasive liver…
-
Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions.
### Background Elevation of liver enzymes in rheumatoid arthritis patients treated with tocilizumab…
-
Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Review
### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…
-
American Association for the Study of the Liver
-
Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…
-
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication
### Background Biopsy is the usual gold standard for liver steatosis assessment. The…
-
Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
**Background/Objectives**: Prior research has identified a significant association between heart disease…
-
The non-invasive assessment of hepatic fibrosis. Review
Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…
-
Non-invasive markers for hepatic fibrosis. Review
With great advancements in the therapeutic modalities used for the treatment of…
-
Noninvasive evaluation of NAFLD. Review
A common clinical concern in patients with NAFLD is whether they have…
-
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…
-
Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.
### Background & Aims Data on liver fibrosis evolution and its involvement in liver…
-
Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. Review
Patients with HIV have a proclivity to develop liver fibrosis, especially when…
-
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication
### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…
-
Predicting significant fibrosis in hepatitis C patients in Luxembourg using serological markers.
### Objective The aim of our study was to assess the diagnostic performance…
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.
### Background Many blood tests have been proposed as alternatives to liver biopsy…
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
Chronic hepatitis C remains a significant medical and economic burden in Canada…
-
Finasteride and methadone use and risk of advanced hepatitis C related liver disease.
### Aim We evaluated the association between two medications that alter bioavailable androgen…
-
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Review
### Background Chronic HCV is one of the major causes of morbidity and…
-
Noninvasive Assessment of Liver Fibrosis.
### Background The prognosis and management of chronic liver diseases greatly depend on…
-
Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.
### Background/Aims Non-invasive markers of liver fibrosis have recently been developed…
-
Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C.
### Introduction The purpose of this clinical trial was to determine in routine…
-
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.
### Background And Aim Significant hepatic fibrosis is prognostic of liver morbidity and…
-
HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.
### Background And Aim Three gene polymorphisms, interferon-lambda-3 (IL28B), inosinetriphosphatase (ITPA…
-
Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).
BACKGROUND: Biochemical marker combinations, including alpha2-macroglobulin, haptoglobin, apolipoprotein A1, gamma-glutamyl…
-
HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
Acute hepatitis C virus infection remains a major health concern in human…
-
Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.
### Background Direct antiviral agents (DAA) showed very good results in terms of…
-
FibroMAX: towards a new universal biomarker of liver disease? Review
Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…
-
The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.
### Importance There is a need for noninvasive tools to monitor hepatotoxicity in…
-
Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.
Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the…
-
A novel panel of blood markers to assess the degree of liver fibrosis.
The objective was to develop new blood tests to characterize different fibrosis…
-
Personalized management of cirrhosis by non-invasive tests of liver fibrosis. Review
Owing to the high prevalence of various chronic liver diseases, cirrhosis is…
-
Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.
As of 2016, there is no evidence-based pathway to stratify the…
-
EASL clinical practical guidelines: management of alcoholic liver disease.
-
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
### Background Blood tests of liver injury are less well validated in non…
-
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.
### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…
-
Noninvasive diagnosis in alcohol-related liver disease.
### Background Alcohol-related liver disease (ALD) represents a major cause of death…
-
Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. Review
The limitations of liver biopsy (invasive procedure, sampling errors, inter-observer variability…
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.
### Background One of the unmet needs in patients with type 2 diabetes…
-
Ministère des Affaires Sociales et de la Santé Key publication
-
Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. Review
### Background Liver fibrosis is a sign of advanced liver disease and is…
-
Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection Key publication
These are the first guidelines dealing with hepatitis C treatment produced by…
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.
In patients with non-alcoholic fatty liver disease (NAFLD) with or without…
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
Mostra l'elenco completo dei risultati. La pagina è renderizzata sul server e non è paginata.